Go to The Journal of Clinical Investigation
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Transfers
  • Advertising
  • Job board
  • Contact
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Immunology
    • Metabolism
    • Nephrology
    • Oncology
    • Pulmonology
    • All ...
  • Videos
  • Collections
    • Resource and Technical Advances
    • Clinical Medicine
    • Reviews
    • Editorials
    • Perspectives
    • Top read articles
  • JCI This Month
    • Current issue
    • Past issues

  • Current issue
  • Past issues
  • Specialties
  • In-Press Preview
  • Editorials
  • Viewpoint
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Transfers
  • Advertising
  • Job board
  • Contact
Hepatic ketogenic insufficiency reprograms hepatic glycogen metabolism and the lipidome
D. André d’Avignon, … , Xianlin Han, Peter A. Crawford
D. André d’Avignon, … , Xianlin Han, Peter A. Crawford
Published June 21, 2018
Citation Information: JCI Insight. 2018;3(12):e99762. https://doi.org/10.1172/jci.insight.99762.
View: Text | PDF
Research Article Hepatology Metabolism

Hepatic ketogenic insufficiency reprograms hepatic glycogen metabolism and the lipidome

  • Text
  • PDF
Abstract

While several molecular targets are under consideration, mechanistic underpinnings of the transition from uncomplicated nonalcoholic fatty liver disease (NAFLD) to nonalcoholic steatohepatitis (NASH) remain unresolved. Here we apply multiscale chemical profiling technologies to mouse models of deranged hepatic ketogenesis to uncover potential NAFLD driver signatures. Use of stable-isotope tracers, quantitatively tracked by nuclear magnetic resonance (NMR) spectroscopy, supported previous observations that livers of wild-type mice maintained long term on a high-fat diet (HFD) exhibit a marked increase in hepatic energy charge. Fed-state ketogenesis rates increased nearly 3-fold in livers of HFD-fed mice, a greater proportionate increase than that observed for tricarboxylic acid (TCA) cycle flux, but both of these contributors to overall hepatic energy homeostasis fueled markedly increased hepatic glucose production (HGP). Thus, to selectively determine the role of the ketogenic conduit on HGP and oxidative hepatic fluxes, we studied a ketogenesis-insufficient mouse model generated by knockdown of the mitochondrial isoform of 3-hydroxymethylglutaryl-CoA synthase (HMGCS2). In response to ketogenic insufficiency, TCA cycle flux in the fed state doubled and HGP increased more than 60%, sourced by a 3-fold increase in glycogenolysis. Finally, high-resolution untargeted metabolomics and shotgun lipidomics performed using ketogenesis-insufficient livers in the fed state revealed accumulation of bis(monoacylglycero)phosphates, which also accumulated in livers of other models commonly used to study NAFLD. In summary, natural and interventional variations in ketogenesis in the fed state strongly influence hepatic energy homeostasis, glucose metabolism, and the lipidome. Importantly, HGP remains tightly linked to overall hepatic energy charge, which includes both terminal fat oxidation through the TCA cycle and partial oxidation via ketogenesis.

Authors

D. André d’Avignon, Patrycja Puchalska, Baris Ercal, YingJu Chang, Shannon E. Martin, Mark J. Graham, Gary J. Patti, Xianlin Han, Peter A. Crawford

×

Figure 4

Increased TCA cycle flux is unmatched by PEP flux, pyruvate cycling, and anaplerosis in livers of ketogenesis-insufficient animals.

Options: View larger image (or click on image) Download as PowerPoint
Increased TCA cycle flux is unmatched by PEP flux, pyruvate cycling, and...
(A) TCA cycle flux; and (B) PEP flux, (C) pyruvate cycling flux, and (D) anaplerotic flux, all normalized to TCA cycle flux, quantified by 2H- and 13C-NMR of monoacetone [13C/2H]glucose derivatized from hepatic venous effluent 13C/2H–labeled glucose from 60-minute perfusions using oxygenated buffer that included 0.2 mM unlabeled sodium octanoate, 3% 2H2O, and 0.2 mM sodium [U-13C]propionate, in the absence or presence of supplemented unlabeled ketone bodies at the indicated concentrations. n = 6–13/group. *P < 0.05; **P < 0.01; ***P < 0.001; ****P < 0.0001 by 2-way ANOVA with Tukey’s post hoc test.

Copyright © 2023 American Society for Clinical Investigation
ISSN 2379-3708

Sign up for email alerts